论文部分内容阅读
自体动静脉内瘘(IAVF)是维持性血液透析(MHD)患者赖以生存的重要生命通路[1],优良的内瘘条件是维持血液透析进行的必须条件。但由于尿毒症患者自身存在的疾病因素,血管条件差、低血压、日积月累的反复穿刺,以及自身对内瘘的护理不当使内瘘血栓形成在所难免。研究表明,血栓形成是导致内瘘失去功能占血液透析患者的14%~36%[2]。因此,尽早治疗内瘘闭塞是延长内瘘使用年限的关键。我科于2015年7月23日对1例内瘘闭塞7 h余患者使用重组人组织型纤溶酶原激酶衍生物(rP A)进行局部溶栓治疗及护理,取得理想效
Autologous arteriovenous fistula (IAVF) is an important life-course for maintenance hemodialysis (MHD) in patients with survival [1], excellent fistula conditions are necessary to maintain hemodialysis. However, due to the existence of uremia patients with their own disease factors, poor vascular conditions, hypotension, repeated puncture over and over again, as well as their own care of fistula improper fistula thrombosis is inevitable. Studies have shown that thrombosis is leading to loss of fistula function of hemodialysis patients 14% to 36% [2]. Therefore, the early treatment of fistula occlusion is to extend the useful life of fistula key. Our department on July 23, 2015 in 1 case of fistula occlusion in more than 7 h patients with recombinant human tissue-type plasminogen kinase (rP A) for local thrombolysis and nursing, and achieved the desired effect